Developer docs
API playgroundTry for free, no card

Search company profiles

Scienture Holdings

Full company profile

uuid02lt926

Namestring
Scienture Holdings
Legal namestring
Scienture Holdings, Inc.
Company typeenum
Public
Founded yearstring
-
Descriptiontext

Scienture Holdings, Inc. (NASDAQ: SCNX) is a Delaware-incorporated specialty pharmaceutical holding company headquartered in Commack, New York, operating through its wholly owned subsidiary Scienture, LLC. The company develops, licenses, and commercializes branded prescription pharmaceutical products in the US market. Its current commercial portfolio consists of two FDA-approved products: REZENOPY (naloxone HCl nasal spray, 10mg), an opioid overdose reversal agent licensed exclusively for US commercialization from Kindeva Drug Delivery and Summit Biosciences in March 2025; and Arbli (losartan potassium oral suspension), an antihypertensive approved by the FDA in March 2025. REZENOPY began commercial shipments to US wholesalers in July 2026, entering a US naloxone market that the company characterizes at approximately $144 million annually and 9.8 million units.

The company's revenue model is built on branded prescription pharmaceutical sales through US wholesale distribution, supported by Group Purchasing Organization (GPO) agreements covering 5,000+ healthcare institutions (~60% of the US institutional market) and payer access covering 100M+ covered lives. Beyond its two approved products, Scienture is developing a pipeline of candidates targeting migraine, thrombosis, and postoperative pain indications, indicating a product-line expansion strategy within specialty therapeutics. The business model relies on regulatory exclusivity from FDA approvals, exclusive licensing arrangements with development partners, and broad institutional channel access to drive prescription volume.

Short descriptiontext

Scienture Holdings is a specialty pharmaceutical holding company that develops and commercializes branded prescription products including REZENOPY (naloxone nasal spray) and Arbli (losartan oral suspension), serving US healthcare institutions and patient populations through wholesale and GPO distribution channels.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersCommack, United States
HQ citystring
Commack
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, naloxone nasal spray, cardiovascular therapeutics, opioid overdose treatment, pharmaceutical distribution
Industry2 codes
PRIMARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Sale of FDA-approved specialty pharmaceutical products including REZENOPY (naloxone HCl nasal spray) and Arbli (losartan potassium oral suspension) to healthcare institutions and through pharmaceutical wholesalers.

globenewswire.com
2Licensing and Commercialization Rights
TypeLicensing Royalties
Description

Exclusive commercial license agreements for proprietary pharmaceutical products, such as the agreement with Kindeva Drug Delivery for REZENOPY and Summit Biosciences for commercialization rights.

sec.gov
Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Scienture, LLC
Description

New York-based pharmaceutical company developing unique specialty products that bring enhanced value to patients and healthcare systems.

scientureholdings.com
Core offering1 text field

Scienture Holdings, Inc. is a specialty pharmaceutical holding company that develops, commercializes, and distributes novel specialty drug products through its wholly-owned subsidiary Scienture, LLC. Its commercial portfolio includes REZENOPY (naloxone HCl nasal spray 10mg), the highest-dose FDA-approved naloxone nasal spray in the U.S., and Arbli (losartan potassium oral suspension) for cardiovascular treatment. The company also maintains a clinical-stage development pipeline focused on cardiovascular and central nervous system diseases.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • REZENOPY targets the $144 million annual U.S. naloxone market
+2 more records
Product overview1 text field

Scienture Holdings, Inc. is a specialty pharmaceutical holding company that operates through its subsidiary Scienture, LLC. The company is focused on developing and commercializing novel specialty products for cardiovascular and central nervous system diseases. Its FDA-approved product portfolio includes REZENOPY (naloxone hydrochloride) Nasal Spray 10 mg, the highest-dose FDA-approved naloxone nasal spray in the U.S., and Arbli (losartan potassium oral suspension). The company also maintains a clinical-stage development pipeline with candidates for migraine, thrombosis, and postoperative pain treatment. The company has secured payer access covering more than 100 million covered lives and has established GPO agreements providing access to over 5,000 healthcare institutions.

Product and service2 records
1REZENOPY (naloxone hydrochloride) Nasal Spray 10 mg
CategorySpecialty Pharmaceuticals — Opioid Overdose Reversal
Description

The highest-dose FDA-approved naloxone hydrochloride nasal spray available in the U.S. market, addressing the approximately $144 million annual U.S. naloxone market for opioid overdose reversal. Sold to U.S. pharmaceutical wholesalers and through GPO agreements to healthcare institutions.

2Arbli (losartan potassium oral suspension)
CategorySpecialty Pharmaceuticals — Cardiovascular
Description

FDA-approved oral suspension formulation of losartan potassium for cardiovascular treatment, received approval through subsidiary Scienture LLC. Provides a liquid dosage option for patients requiring antihypertensive therapy.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-03-01
Description

Exclusive commercial license agreement for REZENOPY (naloxone HCl nasal spray 10mg) signed in March 2025. Kindeva Drug Delivery provides manufacturing and commercialization rights for the highest-dose FDA-approved naloxone nasal spray.

2Summit Biosciences Inc.
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-03-01
Description

Exclusive U.S. commercialization rights agreement for REZENOPY naloxone nasal spray secured in March 2025. This partnership enabled the company to access payer coverage and institutional markets.

stocktitan.net
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Specialty and generic pharmaceutical company with a diversified portfolio across multiple therapeutic areas. Comparable as a small/mid-cap specialty pharma with a similar institutional GPO/wholesaler distribution model.

2Endo International
TypeBroad incumbent
Description

Specialty and generic pharmaceutical company with established CNS, pain, and cardiovascular franchises. Comparable as a specialty pharma with overlapping therapeutic areas including pain and cardiovascular.

TypeDirect peer
Description

Specialty pharmaceutical company focused on opioid use disorder and substance-use treatment. Compares to Scienture given shared focus on the opioid-related therapeutic space and institutional channel distribution.

TypeBroad incumbent
Description

Specialty pharmaceutical company focused on responsible pain management and CNS therapeutics. Comparable given the overlap in CNS therapeutic focus and specialty pharma commercial model.

TypeBroad incumbent
Description

Specialty pharmaceutical company focused on CNS products, particularly in neurology and psychiatry. Comparable given the CNS therapeutic focus that overlaps with Scienture's migraine and pain pipeline.

6Assertio Holdings
TypeBroad incumbent
Description

Specialty pharmaceutical company with branded neurology, inflammation, and pain products. Comparable in scale and therapeutic focus on specialty CNS/pain markets where Scienture's pipeline operates.

TypeBroad incumbent
Description

Global specialty and generic pharmaceutical company with a strong U.S. institutional presence, including injectable and nasal spray products. Comparable business model targeting institutional buyers and wholesalers.

TypeDirect peer
Description

Maker of Narcan, the dominant FDA-approved naloxone nasal spray and the primary direct competitor to REZENOPY. Emergent is the incumbent leader in the U.S. opioid overdose reversal market that Scienture is targeting.

TypeDirect peer
Description

Specialty pharmaceutical manufacturer with a portfolio that includes naloxone injectable products and other hospital-focused injectables. Directly comparable given the institutional/specialty pharma business model and naloxone presence.

TypeBroad incumbent
Description

Global pharmaceutical manufacturer producing generic naloxone and other specialty/generic products. Comparable as a competitor in the naloxone market and as a broader specialty/generic pharma peer.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Scienture Holdings

Specialty Pharmaceuticalsscientureholdings.com

Scienture Holdings is a specialty pharmaceutical holding company that develops and commercializes branded prescription products including REZENOPY (naloxone nasal spray) and Arbli (losartan oral suspension), serving US healthcare institutions and patient populations through wholesale and GPO distribution channels.

What Scienture Holdings does

Scienture Holdings, Inc. (NASDAQ: SCNX) is a Delaware-incorporated specialty pharmaceutical holding company headquartered in Commack, New York, operating through its wholly owned subsidiary Scienture, LLC. The company develops, licenses, and commercializes branded prescription pharmaceutical products in the US market. Its current commercial portfolio consists of two FDA-approved products: REZENOPY (naloxone HCl nasal spray, 10mg), an opioid overdose reversal agent licensed exclusively for US commercialization from Kindeva Drug Delivery and Summit Biosciences in March 2025; and Arbli (losartan potassium oral suspension), an antihypertensive approved by the FDA in March 2025. REZENOPY began commercial shipments to US wholesalers in July 2026, entering a US naloxone market that the company characterizes at approximately $144 million annually and 9.8 million units.

The company's revenue model is built on branded prescription pharmaceutical sales through US wholesale distribution, supported by Group Purchasing Organization (GPO) agreements covering 5,000+ healthcare institutions (~60% of the US institutional market) and payer access covering 100M+ covered lives. Beyond its two approved products, Scienture is developing a pipeline of candidates targeting migraine, thrombosis, and postoperative pain indications, indicating a product-line expansion strategy within specialty therapeutics. The business model relies on regulatory exclusivity from FDA approvals, exclusive licensing arrangements with development partners, and broad institutional channel access to drive prescription volume.

Scienture Holdings firmographics

Firmographics
Name
Scienture Holdings
Legal name
Scienture Holdings, Inc.
Website
https://scientureholdings.com
Company type
Public
Operating status
Operating
Short description
Scienture Holdings is a specialty pharmaceutical holding company that develops and commercializes branded prescription products including REZENOPY (naloxone nasal spray) and Arbli (losartan oral suspension), serving US healthcare institutions and patient populations through wholesale and GPO distribution channels.
Ownership category
akta.pro rank

Scienture Holdings industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Specialty pharmaceuticals
  • Naloxone nasal spray
  • Cardiovascular therapeutics
  • Opioid overdose treatment
  • Pharmaceutical distribution

Where Scienture Holdings is headquartered

Location

Headquarters

HQ city
Commack
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Scienture Holdings business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales: Sale of FDA-approved specialty pharmaceutical products including REZENOPY (naloxone HCl nasal spray) and Arbli (losartan potassium oral suspension) to healthcare institutions and through pharmaceutical wholesalers.
  2. Licensing and Commercialization Rights: Exclusive commercial license agreements for proprietary pharmaceutical products, such as the agreement with Kindeva Drug Delivery for REZENOPY and Summit Biosciences for commercialization rights.

Go-to-market motion2 records

Distribution channels2 records

Scienture Holdings product offering

Product offering

Core offering

Scienture Holdings, Inc. is a specialty pharmaceutical holding company that develops, commercializes, and distributes novel specialty drug products through its wholly-owned subsidiary Scienture, LLC. Its commercial portfolio includes REZENOPY (naloxone HCl nasal spray 10mg), the highest-dose FDA-approved naloxone nasal spray in the U.S., and Arbli (losartan potassium oral suspension) for cardiovascular treatment. The company also maintains a clinical-stage development pipeline focused on cardiovascular and central nervous system diseases.

Product overview

Scienture Holdings, Inc. is a specialty pharmaceutical holding company that operates through its subsidiary Scienture, LLC. The company is focused on developing and commercializing novel specialty products for cardiovascular and central nervous system diseases. Its FDA-approved product portfolio includes REZENOPY (naloxone hydrochloride) Nasal Spray 10 mg, the highest-dose FDA-approved naloxone nasal spray in the U.S., and Arbli (losartan potassium oral suspension). The company also maintains a clinical-stage development pipeline with candidates for migraine, thrombosis, and postoperative pain treatment. The company has secured payer access covering more than 100 million covered lives and has established GPO agreements providing access to over 5,000 healthcare institutions.

Differentiator

Problem solved

Functional benefit

Brands

  • Scienture, LLC: New York-based pharmaceutical company developing unique specialty products that bring enhanced value to patients and healthcare systems.

Products and services

  • REZENOPY (naloxone hydrochloride) Nasal Spray 10 mg The highest-dose FDA-approved naloxone hydrochloride nasal spray available in the U.S. market, addressing the approximately $144 million annual U.S. naloxone market for opioid overdose reversal. Sold to U.S. pharmaceutical wholesalers and through GPO agreements to healthcare institutions.
  • Arbli (losartan potassium oral suspension) FDA-approved oral suspension formulation of losartan potassium for cardiovascular treatment, received approval through subsidiary Scienture LLC. Provides a liquid dosage option for patients requiring antihypertensive therapy.

Quantifiable outcome

  • REZENOPY targets the $144 million annual U.S. naloxone market
  • +2 more outcomes

Companies that use Scienture Holdings

Customer profile

Named customers5 records

Segments2 records

Ideal customer profiles2 records

Scienture Holdings technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Scienture Holdings partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Kindeva Drug DeliverycoreOEM/ Whitelabel/ Licensing Partner · 1 March 2025Exclusive commercial license agreement for REZENOPY (naloxone HCl nasal spray 10mg) signed in March 2025. Kindeva Drug Delivery provides manufacturing and commercialization rights for the highest-dose FDA-approved naloxone nasal spray.
  • Summit Biosciences Inc.coreOEM/ Whitelabel/ Licensing Partner · 1 March 2025Exclusive U.S. commercialization rights agreement for REZENOPY naloxone nasal spray secured in March 2025. This partnership enabled the company to access payer coverage and institutional markets.

Scale indicators5 records

Recent moves7 records

Expansion highlights3 records

Scienture Holdings competitors and assessment

Company assessment

Broad incumbents

  • ANI Pharmaceuticals: Specialty and generic pharmaceutical company with a diversified portfolio across multiple therapeutic areas. Comparable as a small/mid-cap specialty pharma with a similar institutional GPO/wholesaler distribution model.
  • Endo International: Specialty and generic pharmaceutical company with established CNS, pain, and cardiovascular franchises. Comparable as a specialty pharma with overlapping therapeutic areas including pain and cardiovascular.
  • Collegium Pharmaceutical: Specialty pharmaceutical company focused on responsible pain management and CNS therapeutics. Comparable given the overlap in CNS therapeutic focus and specialty pharma commercial model.
  • Supernus Pharmaceuticals: Specialty pharmaceutical company focused on CNS products, particularly in neurology and psychiatry. Comparable given the CNS therapeutic focus that overlaps with Scienture's migraine and pain pipeline.
  • Assertio Holdings: Specialty pharmaceutical company with branded neurology, inflammation, and pain products. Comparable in scale and therapeutic focus on specialty CNS/pain markets where Scienture's pipeline operates.
  • Hikma Pharmaceuticals: Global specialty and generic pharmaceutical company with a strong U.S. institutional presence, including injectable and nasal spray products. Comparable business model targeting institutional buyers and wholesalers.
  • Teva Pharmaceutical Industries: Global pharmaceutical manufacturer producing generic naloxone and other specialty/generic products. Comparable as a competitor in the naloxone market and as a broader specialty/generic pharma peer.

Direct peers

  • Indivior: Specialty pharmaceutical company focused on opioid use disorder and substance-use treatment. Compares to Scienture given shared focus on the opioid-related therapeutic space and institutional channel distribution.
  • Emergent BioSolutions: Maker of Narcan, the dominant FDA-approved naloxone nasal spray and the primary direct competitor to REZENOPY. Emergent is the incumbent leader in the U.S. opioid overdose reversal market that Scienture is targeting.
  • Amphastar Pharmaceuticals: Specialty pharmaceutical manufacturer with a portfolio that includes naloxone injectable products and other hospital-focused injectables. Directly comparable given the institutional/specialty pharma business model and naloxone presence.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Scienture Holdings financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Scienture Holdings leadership team

Management profile

Number of profiles

Profiles1 record

Scienture Holdings subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Scienture Holdings funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Scienture Holdings M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Scienture Holdings

What does Scienture Holdings do?

Scienture Holdings, Inc. is a specialty pharmaceutical holding company that develops, commercializes, and distributes novel specialty drug products through its wholly-owned subsidiary Scienture, LLC. Its commercial portfolio includes REZENOPY (naloxone HCl nasal spray 10mg), the highest-dose FDA-approved naloxone nasal spray in the U.S., and Arbli (losartan potassium oral suspension) for cardiovascular treatment. The company also maintains a clinical-stage development pipeline focused on cardiovascular and central nervous system diseases.

Is Scienture Holdings a public or private company?

Scienture Holdings is a public company. It is classified as public and is currently operating.

When was Scienture Holdings founded?

Scienture Holdings was founded in -1.

Where is Scienture Holdings based?

Scienture Holdings is headquartered in Commack, United States, in the North America region.

How does Scienture Holdings make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing and Commercialization Rights.

Who are Scienture Holdings's main competitors?

Broad incumbents on record are ANI Pharmaceuticals, Endo International, Collegium Pharmaceutical, Supernus Pharmaceuticals, Assertio Holdings, Hikma Pharmaceuticals and Teva Pharmaceutical Industries. Direct peers are Indivior, Emergent BioSolutions and Amphastar Pharmaceuticals.

Does Scienture Holdings have an API?

No public API is recorded for Scienture Holdings.

What industry is Scienture Holdings in?

Scienture Holdings's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIACAG, Cardiology & Vascular Specialty Pharmaceuticals, with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Quiver QuantitativeScienture Holdings Reports Q2 2026 Results, Launches REZENOPY™ and Narrows Losses | SCNX Stock NewsScienture Holdings reported a 510% sequential increase in Q2 2026 revenue to $343,639 and narrowed its net loss by 58% year-over-year while commencing the commercial launch of its second product, REZENOPY. The company secured patent protections for both REZENOPY and its existing product Arbli, expanded payer coverage for Arbli, and strengthened its cash position to approximately $11.2 million. Management expressed confidence in achieving profitability by 2027 driven by these two FDA-approved products and improved operational efficiency.YahooSCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating PerformanceScienture Holdings reported Q2 2026 financial results showing a 510% sequential revenue increase to $343,639 and significant improvements in operating metrics, including narrowed net losses. The company also commenced the commercial launch of its second product, REZENOPY™, while expanding payer coverage for its existing hypertension drug, Arbli™.Stock TitanScienture Q2 2026 Earnings: Revenue Rises ~510%Scienture Holdings reported a 510% sequential increase in Q2 2026 revenue to approximately $343,639, driven by the commercial launch of its product REZENOPY and continued sales of Arbli. The company narrowed its net loss by 58% year-over-year to roughly $2.8 million while securing formulary coverage for REZENOPY and expanding payer access for Arbli.BioSpaceSCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating PerformanceScienture reported Q2 2026 revenue of $343,639, up 510% sequentially from $56,325 in Q1 2026. The company's net loss narrowed 58% year-over-year to $2.8 million, and gross margin reached 97.7%. It also launched REZENOPY, its second commercial product, and expanded Arbli's payer coverage.AInvestWhy Is SCNX Stock Dropping Today? Scienture Holdings Falls After REZENOPY Commercial LaunchScienture Holdings shares dropped 11.33% in pre-market trading after announcing the commercial launch of its FDA-approved product, REZENOPY. The decline was driven by a "sell the news" reaction as investors took profits due to the absence of immediate revenue guidance and lack of financial projections for the new drug.AdvfnSCIENTURE Launches REZENOPY as Second FDA-Approved Commercial ProductSCIENTURE has commercially launched REZENOPY, a 10 mg naloxone nasal spray for opioid overdose treatment, fulfilling initial orders to U.S. pharmaceutical wholesalers and commencing nationwide distribution. The company holds exclusive commercialization rights through an agreement with Summit Biosciences and has secured payer coverage for over 100 million lives alongside GPO agreements with more than 5,000 healthcare facilities. This launch marks SCIENTURE's second FDA-approved product, shifting focus from regulatory approval to revenue generation and market adoption.Investing.comScienture launches naloxone nasal spray for opioid overdose By Investing.comScienture Holdings Inc. announced the commercial launch of REZENOPY, a 10 mg naloxone hydrochloride nasal spray for opioid overdose treatment, and has begun fulfilling purchase orders with U.S. pharmaceutical wholesalers. The company has secured commercial payer coverage for over 100 million lives and agreements with Group Purchasing Organizations to access more than 5,000 healthcare facilities.YahooSCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal SprayScienture Holdings, Inc. announced the commercial launch of REZENOPY™, its 10 mg naloxone nasal spray, and confirmed the fulfillment of initial purchase orders to U.S. pharmaceutical wholesalers. The company is targeting continued execution through 2026 by expanding payer coverage for over 100 million lives and securing access to more than 5,000 healthcare facilities via Group Purchasing Organization agreements.YahooEXCLUSIVE: Scienture Launches Highest-Dose Naloxone Nasal Spray Rezenopy in USScienture Holdings Inc. has launched Rezenopy, a 10-milligram naloxone nasal spray, initiating its commercial rollout and distribution to wholesalers across the United States. This launch marks the nationwide distribution of the company's second FDA-approved product, supported by exclusive rights secured from Summit Biosciences and significant payer coverage extending to over 100 million individuals. The move positions Scienture to potentially capture a major share of the domestic institutional naloxone market as it targets hospitals, pharmacies, and emergency services.BenzingaEXCLUSIVE: Scienture Launches Highest-Dose Naloxone Nasal Spray Rezenopy in US - Scienture Holdings (NASDScienture Holdings initiated the commercial rollout of Rezenopy, a 10-milligram naloxone nasal spray, marking its second FDA-approved product. The company has secured exclusive domestic rights through an agreement with Summit Biosciences and established institutional access via Group Purchasing Organization agreements targeting over 5,000 healthcare locations.